• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » TSRI awarded $1.4M for chronic leukemia research

TSRI awarded $1.4M for chronic leukemia research

June 27, 2013
CenterWatch Staff

Scientists from The Scripps Research Institute (TSRI) have been awarded more than $1.4 million from the National Cancer Institute of NIH to create a potential new drug to attack the malignant cells that cause chronic lymphocytic leukemia (CLL).

Christoph Rader, a TSRI associate professor, will be principal investigator of the new three-year study. William Roush, a TSRI professor, associate dean of graduate studies and executive director of medicinal chemistry, will be co-principal investigator.

CLL affects approximately 150,000 patients and causes 4,500 deaths per year in the U.S. While chemotherapy and radiation are used to treat this slow growing form of leukemia, there are no therapeutic options for the disease in which physicians can selectively target the malignant cells yet spare normal cells and tissues.

The scientists plan to use the recently discovered cell surface receptor TOSO, which is overexpressed in leukemia cells, to create a rapid and effective entry point for delivering drugs to these malignant cells while bypassing normal cells as much as possible.

"We want to create carrier-payload combinations to deliver cytotoxic drugs with very specific targeting," said Roush. "Once we have accomplished that, we expect to optimize potency."

The team plans to use an antibody fragment to add a second target to the treatment—the receptor tyrosine kinase ROR1, which is expressed exclusively on leukemia cells.

"This dual-targeting strategy will lay the foundation for further preclinical and clinical investigations in the treatment of this form of leukemia," said Rader. "We also think that the novel biological and chemical components that come from this study can be exploited to develop combinations for diseases beyond CLL."

Rader also has been selected to receive a two year $250,000 grant from the Lymphoma Research Foundation. That study will use a similar technology for targeting the receptor tyrosine kinase ROR1 in mantle cell lymphoma, a rare and difficult to treat form of non-Hodgkin lymphoma.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing